DWIHN president: Rumor about no longer accepting walk in patients is false
DETROIT (FOX 2) - After a rumor began circulating on social media platforms that the Detroit Wayne Integrated Health Network was no longer accepting voluntary admissions, the group quickly said that was not true.
"There is absolutely no truth to the rumor being circulated on social media that the Detroit Wayne Integrated Health Network is no longer accepting voluntary admissions," said President and CEO James White. "In the month of February alone, the Crisis Care Center voluntarily served 94 individuals and since the false information was posted two days ago, we had 10 voluntary admissions."
A post originated on Reddit, in the Detroit sub-reddit, and quickly spread to other platforms, claimed that the health network was no longer taking walk in patients. It appeared to be from someone connected to DWIHN, but was posted anonymously.
"Previously, it was all voluntary. Today, if you want to recieve services you would be petitioned. Petition means held up to 72-hours by court order," the post read in part. "This news came out today that all employees. Still trying to figure out why this change happened as it goes against the agency values and our professions values."
The poster, going by the handle "regular_shake8324," implied in a response to the post that they would be "doxing" themselves to reveal more about how they knew about the change.
DWIHN said that change was never instituted.
"This is absolutely false. This Crisis Care Center is one of the jewels of the city of Detroit and we will always help people no matter if they are dropped off by law enforcement, have an appointment or just show up. We are here to serve our Wayne County citizens," said White.
The 707 Crisis Care Center, located in the heart of the city of Detroit, provides direct specialized care for children and adults in crisis, hoping to ease the burden on local emergency departments which are not always equipped to offer appropriate mental health support. The Center is unique because all the services are under one roof, Crisis Walk-In, Crisis Stabilization, and a peer-led program called BEST (Building Empowered Supportive Transition).
The Crisis Care Center is a place where adults and adolescents in a behavioral health crisis can be evaluated to determine their medical necessity for crisis level services. The 32-bed facility has 12 adult beds and 6 for children ages 5 to 17. Individuals can also receive non-crisis behavioral health services on the 3rd floor of the Milwaukee building at DWIHN's new Community Care Clinic. A second clinic is located on West McNichols and Greenfield which just opened up two weeks ago.
Anyone in crisis can walk-in or call the Crisis Care Center at 313-989-9444 or the DWIHN 24/7 Access Helpline at 800-241-4949 and you will get connected to the services and supports you need.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 hours ago
- Yahoo
Doctor: Many prostate cancer screenings involve only a blood test
DETROIT (FOX 2) - When it comes to detecting prostate cancer, it can be a little confusing. Like what does the screening involve and who should get screened, and when? "It's not a death sentence, it's a life sentence," said Dr. Michael Lutz. "It's important to get screened and know if you're at risk." Big picture view Lutz, the president of the Michigan Men's Health Foundation, says there is plenty of living to do after a prostate cancer diagnosis. You have to catch it early. Who's at greatest risk? "We know there are certain men at risk," he said, "Family history, African American, firefighter, fighter pilot - these are going to increase risk." Screening for prostate cancer involves a blood test, the PSA and now Dr. Lutz says the slightly uncomfortable part of the exam, might not be needed. "A lot of men don't want to get screened because of the digital rectal exam rather get a rectal exam - they would rather get bit by cobra," Lutz said. "Get the PSA blood test first. If its low you don't need rectal exam." For those at higher risk, screening can start at 40. Those with average risk it's recommended men start screenings at 50. But the recommendations get murky when it comes to men over the age of 70. Lutz says be your own advocate and ask for the screening no matter your age. "Don't let your chronological age be your determining factor," he said. This weekend, on Father's Day - the Run for the Ribbon is happening at the Detroit Zoo. Everyone is welcome to celebrate survival of prostate cancer. Get more info by tapping in September - get ready for the annual Men's Health Event at Ford Field. Some of the money raised at run for the ribbon will fund the Men's Health Event at Ford Field. That's an incredible event that offers life-changing screenings. The Source This report was based off an interview with Dr, Michael Lutz.
Medscape
a day ago
- Medscape
SGLT2 Inhibitors May Offer Better Delirium Protection in T2D
In adults with type 2 diabetes (T2D), the use of SGLT2 inhibitors was associated with lower risks for delirium and all-cause mortality than the use of metformin, with more prominent protective effects in high-risk patients such as those aged 80 years or older. METHODOLOGY: T2D is a recognized risk factor for delirium. Although several studies have shown neuroprotective effects of metformin and cognitive protection by SGLT2 inhibitors, a real-world comparative analysis is lacking. Researchers conducted a retrospective cohort study using data from electronic health records of healthcare organizations worldwide for a head-to-head comparison of metformin and SGLT2 inhibitors in preventing delirium among patients with T2D. After propensity score matching, they included adults with T2D who initiated either SGLT2 inhibitors (n = 79,723; mean age, 65.52 years; 39.77% women) or metformin (n = 79,723; mean age, 65.62 years; 39.43% women) between January 2005 and January 2025. The primary outcome was the first recorded diagnosis of delirium, and the secondary outcome was all-cause mortality. TAKEAWAY: The use of SGLT2 inhibitors was associated with a lower risk for incident delirium than the use of metformin (adjusted hazard ratio [aHR], 0.91; 95% CI, 0.87-0.95). The risk for all-cause mortality was also reduced in patients who used SGLT2 inhibitors (aHR, 0.85; 95% CI, 0.87-0.88). The protective effect of SGLT2 inhibitors against delirium was most prominent in patients aged 80 years or older (aHR, 0.83; P < .0001), men (aHR, 0.94; P = .0131), White patients (aHR, 0.90; P < .0001), and patients with better glycemic control with A1c levels between 5% and 6.49% (aHR, 0.91; P = .0212). < .0001), men (aHR, 0.94; = .0131), White patients (aHR, 0.90; < .0001), and patients with better glycemic control with A1c levels between 5% and 6.49% (aHR, 0.91; = .0212). Among patients who used SGLT2 inhibitors, the use of medicines such as insulin, sulfonylureas, antiepileptics, and sedatives was also associated with a significantly reduced risk for delirium ( P < .05 for all). IN PRACTICE: 'By leveraging real-world data on an unprecedented scale, this study not only bridges a critical knowledge gap but also paves the way for a paradigm shift in first-line diabetes management, prioritizing both metabolic and neurocognitive health,' the study authors wrote. SOURCE: This study was led by Mingyang Sun and Xiaoling Wang, Department of Anesthesiology and Perioperative Medicine, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital in Zhengzhou, China. It was published online in Diabetes Care . LIMITATIONS: The researchers relied on diagnostic codes which may have missed milder cases of delirium, especially those managed outside hospital settings. The presence of residual confounding factors could not be completely ruled out. Information on neurocognitive markers was absent, which restricted the understanding of the neuroprotective effects of SGLT2 inhibitors. DISCLOSURES: This study was supported by grants from National Key Research and Development Program of China, National Natural Science Foundation of China, and Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital. The authors reported having no conflicts of interest.
Medscape
a day ago
- Medscape
Family Ties May Shape Hashimoto Thyroiditis Risk
The odds of developing Hashimoto thyroiditis (HT) were significantly elevated in first-, second-, and third-degree relatives of patients with HT, with female relatives having a disproportionately higher likelihood. Of note, the odds of developing HT were elevated among spouses of patients. METHODOLOGY: Relatives of patients with HT are at an increased risk for HT; however, studies have primarily focused on first-degree relatives and often employed very small sample sizes. Researchers conducted a retrospective case-control study using genealogical and medical data from a Utah-based database (1996-2021) to estimate the risk for HT in relatives across various degrees of relatedness. They included 92,405 adult HT probands (73% women; 96% White individuals) and 184,810 matched control individuals, along with 2,960,650 first-, second-, and third-degree relatives of HT probands and 5,730,159 relatives of control individuals. TAKEAWAY: Relatives of patients with HT were at an increased risk for the condition, with the highest odds observed for first-degree relatives (odds ratio [OR], 1.77; 95% CI, 1.74-1.80), followed by second-degree (OR, 1.23; 95% CI, 1.22-1.27) and third-degree (OR, 1.11; 95% CI, 1.10-1.12) relatives. The risk for HT was an additional 2.2- to 2.6-fold higher in female relatives of patients with HT than overall estimates, across all degrees of relatedness. Among first-degree relatives, sons of men with HT had a markedly elevated risk for HT (OR, 2.36; 95% CI, 2.10-2.65). Wives of men with HT and husbands of women with HT were at an increased likelihood of developing HT, suggesting the effect of a shared environment. IN PRACTICE: 'These findings also have clinical implications, as understanding familial clustering of HT can help healthcare providers identify individuals at higher risk, especially those with affected FDRs [first-degree relatives]. This knowledge could lead to earlier monitoring and intervention, improving disease management,' the authors of the study wrote. SOURCE: This study was led by Melissa Bujnis, PhD, Department of Human Genetics, University of Utah, Salt Lake City. It was published online in The Journal of Clinical Endocrinology & Metabolism . LIMITATIONS: Reliance on diagnostic codes may have introduced misclassification bias, particularly in cases of transient hypothyroidism or misdiagnosed HT. Variations in diagnostic practices across clinics may have introduced heterogeneity in the sample. Individuals with a family history of HT might be more likely to receive diagnosis or seek medical attention, potentially introducing ascertainment bias. DISCLOSURES: Partial support for the datasets in the database was provided by the University of Utah, Huntsman Cancer Institute, National Institutes of Health (NIH). This study received support from NIH, NCRR, and Utah Department of Health and Human Services and the University of Utah. The authors reported no relevant conflicts of interest.
